ARTES offers a brand-new business area making the hearts of all R&D staff beat faster. We have a whole range of first-class antigens, enzymes and functional proteins just waiting to be used in new, exciting projects.
Ovid Therapeutics - Jeremy LevinBy Jeremy Levin, D.Phil, MB BChir
DFE Pharma, a world leader in excipients, has expanded into the biopharmaceutical market with its BioHale® portfolio, specifically designed for biologics.
Asabys PartnersAsabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
2024 Cytiva, Reproduced with Permission of OwnerThe biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.
Jeremy Levin, Ovid TherapeuticsThe U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.
Download Hamilton’s comprehensive white paper and explore what PAT (Process Analytical Technology) means in Biopharma Upstream processes. Discover cutting-edge sensor solutions to effectively monitor critical process parameters and ensure product quality and reproducibility.
SR-TigitItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.
Image by freepikAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
CDC/Phil_ImagesLondon-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline programme.